Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gossamer Bio stock | 9.17

Own Gossamer Bio stock in just a few minutes.

Posted

Fact checked

Gossamer Bio, Inc is a biotechnology business based in the US. Gossamer Bio shares (GOSS) are listed on the NASDAQ and all prices are listed in US Dollars. Gossamer Bio employs 171 staff and has a market cap (total outstanding shares value) of USD$696.9 million.

How to buy shares in Gossamer Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gossamer Bio. Find the stock by name or ticker symbol: GOSS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gossamer Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$9.17, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Gossamer Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gossamer Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Gossamer Bio's share price?

Since the stock market crash in March caused by coronavirus, Gossamer Bio's share price has had significant negative movement.

Its last market close was USD$9.17, which is 38.83% down on its pre-crash value of USD$14.99 and 21.94% up on the lowest point reached during the March crash when the shares fell as low as USD$7.52.

If you had bought USD$1,000 worth of Gossamer Bio shares at the start of February 2020, those shares would have been worth USD$687.65 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$672.25.

Gossamer Bio share price

Use our graph to track the performance of GOSS stocks over time.

Gossamer Bio shares at a glance

Information last updated 2020-10-19.
Latest market close USD$9.17
52-week range USD$7.52 - USD$27.1497
50-day moving average USD$12.4437
200-day moving average USD$12.8068
Wall St. target price USD$24.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-5.949

Buy Gossamer Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gossamer Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gossamer Bio price performance over time

Historical closes compared with the close of $9.17 from 2020-11-16

1 week (2020-11-20) 1.78%
1 month (2020-10-27) -3.78%
3 months (2020-08-27) -30.69%
6 months (2020-05-27) -22.81%
1 year (2019-11-27) -63.29%
2 years (2018-11-23) N/A
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

Gossamer Bio financials

Gross profit TTM USD$0
Return on assets TTM -22.82%
Return on equity TTM -52.02%
Profit margin 0%
Book value $5.84
Market capitalisation USD$696.9 million

TTM: trailing 12 months

Shorting Gossamer Bio shares

There are currently 9.9 million Gossamer Bio shares held short by investors – that's known as Gossamer Bio's "short interest". This figure is 21% up from 8.1 million last month.

There are a few different ways that this level of interest in shorting Gossamer Bio shares can be evaluated.

Gossamer Bio's "short interest ratio" (SIR)

Gossamer Bio's "short interest ratio" (SIR) is the quantity of Gossamer Bio shares currently shorted divided by the average quantity of Gossamer Bio shares traded daily (recently around 476597.53384913). Gossamer Bio's SIR currently stands at 20.68. In other words for every 100,000 Gossamer Bio shares traded daily on the market, roughly 20680 shares are currently held short.

However Gossamer Bio's short interest can also be evaluated against the total number of Gossamer Bio shares, or, against the total number of tradable Gossamer Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gossamer Bio's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Gossamer Bio shares in existence, roughly 140 shares are currently held short) or 0.1767% of the tradable shares (for every 100,000 tradable Gossamer Bio shares, roughly 177 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Gossamer Bio.

Find out more about how you can short Gossamer Bio stock.

Gossamer Bio share dividends

We're not expecting Gossamer Bio to pay a dividend over the next 12 months.

Gossamer Bio overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site